•  
  •  
  •  
  •  

2026-02-15 02:19:10

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Anupam Rasayan Delivers Strong Q3 FY26 Performance
  • Hind Rectifiers Posts Record Q3 FY26 Revenue
  • AvenuesAI Reports Record Q3 FY26 with 122% Revenue Growth
  • Vipul Organics Reports Solid Q3 FY26 Growth
  • KFin Technologies Posts Robust Q3 FY26 Growth

Keywords Selected:  Study

Research

  • Non-Metro banking customers prioritize insurance and transparency while metro customers favour lifestyle perks: Ujjivan SFB Study
  • Godrej Interio's 'HomeScapes' Study reveals Indians want ‘Me-Time’ at home
  • Rising frauds propel demand for AI/ML strategies: Experian Study
  • 96% of MSMEs expect profits to rise in 2023, says NeoGrowth's MSME Business Confidence Study

Market Commentary

  • India's ₹23.43 Lakh Crore Alternatives Boom: PMS and AIF Assets Mark a Decade of High-Conviction Growth and Portfolio Transformation

Stock Report

  • AI Will Be Key Driver for Margin Gains in 2026 finds TCS FutureReady Manufacturing Study
  • Hexaware Debuts Strongly in Whitelane Research 2025 German IT Sourcing Study
  • Harvard Business Publishing Features Manappuram Finance's Leadership Strategies and HR Practices as Case Study
  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • AI and Digital Twins Set to Redefine Aerospace by 2035, reveals TCS Study
  • KP Group Featured in IBM Global Case Study on Scaling Clean Energy with Intelligent Asset Monitoring
  • Hexaware Ranked #1 in Overall Client Satisfaction in Whitelane UK & Ireland IT Sourcing Study 2025
  • Hexaware ranked First in General Satisfaction in Whitelane Study for Europe
  • 2025 to be the year of electric vehicles: 64% of Consumers Likely to Choose EV as Their Next Vehicle, reveals TCS global Study
  • Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma
  • Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant
  • RateGain's Growth Story Becomes an NYU SPS Case Study
  • Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant
  • Ahasolar Technologies Ltd receives order worth Rs. 18 lakhs
  • Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
  • 50% of Indian SMEs prioritize Cloud for business expansion in FY2024, finds 'SME Digital Insights' Study
  • Coforge Named 'Exceptional Performer' in Whitelane Research's 2024 UK IT Sourcing Study
  • Sun Pharma and Moebius Medical Ltd present Phase 2b study on MM-II
  • SPARC announces results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease
  • Crompton Built-In Kitchen Appliances recognized as outstanding modern marketing case study
  • Zydus receives approval from USFDA to initiate Phase II clinical trial of ZYIL1 in patients with Parkinson's disease
  • Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
  • LTIMindtree ranks Second in Overall Customer Satisfaction in Whitelane Research's 2023 IT Sourcing Study for Germany

Latest Post

  • Anupam Rasayan Delivers Strong Q3 FY26 Performance
  • Hind Rectifiers Posts Record Q3 FY26 Revenue
  • AvenuesAI Reports Record Q3 FY26 with 122% Revenue Growth
  • Vipul Organics Reports Solid Q3 FY26 Growth
  • KFin Technologies Posts Robust Q3 FY26 Growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025